As with the CTGF hemizygous deletion mice, the mdx mice treated with CTGF-specific antibody exhibited improved muscle strength and less skeletal muscle damage compared to the mdx control mice [17,58], which implies that CTGF is a potent therapeutic target in the regulation of the progression of fibrosis in DMD. The gene discussed is CCN2; the disease is Duchenne muscular dystrophy.